US 12,259,396 B2
Methods and compositions for assessing antibody specificities
Patrick Sean Daugherty, Goleta, CA (US); Kathryn Vinaya Louise Kamath, Santa Barbara, CA (US); and Jack Ryan Reifert, Santa Barbara, CA (US)
Assigned to Serimmune Inc., Goleta, CA (US)
Filed by Serimmune Inc., Goleta, CA (US)
Filed on Jun. 14, 2024, as Appl. No. 18/744,293.
Application 18/744,293 is a continuation of application No. 18/243,566, filed on Sep. 7, 2023, granted, now 12,146,884.
Application 18/243,566 is a continuation of application No. 18/122,527, filed on Mar. 16, 2023.
Application 18/122,527 is a continuation of application No. 17/096,890, filed on Nov. 12, 2020, granted, now 11,828,762.
Application 17/096,890 is a continuation of application No. 16/544,652, filed on Aug. 19, 2019, granted, now 10,871,494, issued on Dec. 22, 2020.
Application 16/544,652 is a continuation of application No. 15/991,982, filed on May 29, 2018, granted, now 10,386,373, issued on Aug. 20, 2019.
Application 15/991,982 is a continuation of application No. 15/775,363, abandoned, previously published as PCT/US2016/061929, filed on Nov. 14, 2016.
Claims priority of provisional application 62/339,644, filed on May 20, 2016.
Claims priority of provisional application 62/253,926, filed on Nov. 11, 2015.
Prior Publication US 2024/0402189 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); C07K 14/195 (2006.01); C07K 14/285 (2006.01); C07K 14/315 (2006.01); C07K 14/435 (2006.01); C07K 14/44 (2006.01); C07K 14/45 (2006.01); C12N 15/10 (2006.01); C12Q 1/689 (2018.01); G01N 33/53 (2006.01); G01N 33/564 (2006.01); G01N 33/569 (2006.01)
CPC G01N 33/6854 (2013.01) [C07K 14/195 (2013.01); C07K 14/285 (2013.01); C07K 14/315 (2013.01); C07K 14/43554 (2013.01); C07K 14/44 (2013.01); C07K 14/45 (2013.01); G01N 33/53 (2013.01); G01N 33/564 (2013.01); G01N 33/569 (2013.01); G01N 33/56905 (2013.01); G01N 33/56911 (2013.01); G01N 33/56944 (2013.01); G01N 33/56966 (2013.01); G01N 33/56983 (2013.01); G01N 33/56988 (2013.01); G01N 33/56994 (2013.01); G01N 33/6842 (2013.01); G01N 33/6845 (2013.01); G01N 33/6878 (2013.01); C12N 15/1037 (2013.01); C12Q 1/689 (2013.01); G01N 2333/045 (2013.01); G01N 2333/05 (2013.01); G01N 2333/095 (2013.01); G01N 2333/16 (2013.01); G01N 2333/18 (2013.01); G01N 2333/20 (2013.01); G01N 2333/285 (2013.01); G01N 2333/29 (2013.01); G01N 2333/315 (2013.01); G01N 2333/4353 (2013.01); G01N 2570/00 (2013.01); G01N 2800/24 (2013.01); G01N 2800/26 (2013.01); Y02A 50/30 (2018.01)] 30 Claims
 
1. An array comprising a peptide comprising a binding motif sequence [LI]xxA[ILV]xxRG (SEQ ID NO: 362), [DA]DPTN (SEQ ID NO: 367), or KETPPALN (SEQ ID NO: 421), wherein a length of the peptide comprising the binding motif sequence is 30 amino acids or less, and wherein the peptide is operably linked to an array surface to present the peptide for binding by an antibody, wherein the array surface comprises:
(i) a solid surface, wherein the peptide is attached to the solid surface, or
(ii) a biological particle, wherein the biological particle is engineered to express the peptide operably linked to a display scaffold, wherein the display scaffold is configured to display the peptide on the outer surface of the biological particle, and wherein the amino acid sequence of the peptide is heterologous to the biological particle.